News

Fierce Biotech1h

Akeso scores twice in pair of phase 3 trials, teeing up regulatory submission in China

Gumokimab, also called AK111, is an anti-IL-17A monoclonal antibody that Akeso has already tested out in a separate phase 3 ...
Fierce Biotech4h

After layoffs, a CNS biotech attempts to break IPO ice for phase 3 funding

Amid a frozen over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its ...
Fierce Biotech4h

Arnatar unveils with $52M, a dual-modality RNA platform and rare disease asset

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...
Fierce Biotech4h

After month-long delay, Coya Therapeutics receives FDA go-ahead for ph. 2 ALS trial

With the FDA’s go-ahead, Coya plans to launch a multicenter phase 2 trial of COYA 302 in patients with ALS, CEO Arun ...
Fierce Biotech5h

AbbVie tunes in to Gilgamesh’s story, inking $1.2B deal for psychedelic program

At AbbVie, bretisilocin will slot into a well-established neuroscience unit. AbbVie has deals with Gedeon Richter, the source ...
Fierce Biotech6h

PDS reports 39 months overall survival in Keytruda combination head and neck cancer trial

PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...